Zolmitriptan

Zolmitriptan is a selective serotonin receptor agonist. (In Vitro) :Zolmitriptan (311C90) exhibits higher affinity to 5-HT than sumatriptan (pKA=6.63±0.04 and 6.16±0.03, respectively) . 311C90 displays high affinity at human recombinant 5-HT1D and 5-HT1B receptors in transfected CHO-K1 cell membranes (pIC50 values=9.16±0.12 and 8.32±0.09, respectively) . (In Vivo) :Zolmitriptan (311C90; 3-30 μg/kg, i.v.) causes a dose-dependent inhibition of [125I]-albumin extravasation within the ipsilateral dura mater. Zolmitriptan also produces dose-dependent falls in cranial vascular conductance (32.3% at 30 μg/kg) . Zolmitriptan is an anti-migraine agent with action at 5-HT1B/D receptors. Zolmitriptan is an effective and behaviorally specific anti-aggressive agent in situations that engender moderate and alcohol-heightened levels of aggression. Zolmitriptan (1-30 mg/kg, i.p.) exerts behaviorally specific anti-aggressive effects in mice."